LZ Technology Holdings Limited Class B Ordinary Shares (LZMH) - Total Liabilities
Based on the latest financial reports, LZ Technology Holdings Limited Class B Ordinary Shares (LZMH) has total liabilities worth $441.82 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore LZ Technology Holdings Limited Class B O (LZMH) cash flow conversion to assess how effectively this company generates cash.
LZ Technology Holdings Limited Class B Ordinary Shares - Total Liabilities Trend (2021–2024)
This chart illustrates how LZ Technology Holdings Limited Class B Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of LZ Technology Holdings Limited Class B O to evaluate the company's liquid asset resilience ratio.
LZ Technology Holdings Limited Class B Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of LZ Technology Holdings Limited Class B Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Spring Art Holdings Bhd
KLSE:0216
|
Malaysia | RM17.85 Million |
|
Nusantara Voucher Distribution Tbk PT
JK:DIVA
|
Indonesia | Rp33.84 Billion |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:PHH
|
USA | $1.58 Million |
|
Sejin T.S Co.Ltd
KQ:067770
|
Korea | ₩1.08 Billion |
|
NEXE Innovations Inc
V:NEXE
|
Canada | CA$2.85 Million |
|
Cherry AG
XETRA:C3RY
|
Germany | €73.87 Million |
|
Bal Pharma Limited
NSE:BALPHARMA
|
India | Rs2.71 Billion |
|
Mico BioMed Co. Ltd.
KQ:214610
|
Korea | ₩7.88 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down LZ Technology Holdings Limited Class B Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LZMH market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.86 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LZ Technology Holdings Limited Class B Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LZ Technology Holdings Limited Class B Ordinary Shares (2021–2024)
The table below shows the annual total liabilities of LZ Technology Holdings Limited Class B Ordinary Shares from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $238.17 Million | +6.10% |
| 2023-12-31 | $224.47 Million | +108.62% |
| 2022-12-31 | $107.60 Million | -36.67% |
| 2021-12-31 | $169.89 Million | -- |
About LZ Technology Holdings Limited Class B Ordinary Shares
LZ Technology Holdings Limited operates as an information technology and advertising company in China. The company offers smart community services, including intelligent community building access devices and safety management systems through access control monitors and vendor-provided SaaS platforms. It also provides out-of-home advertising solutions, which offer one-stop multi-channel advertisin… Read more